Solventum Corporation (SOLV)
| Market Cap | 15.61B +26.1% |
| Revenue (ttm) | 8.31B -0.9% |
| Net Income | 1.43B +277.4% |
| EPS | 8.19 +275.1% |
| Shares Out | 170.22M |
| PE Ratio | 11.19 |
| Forward PE | 13.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 576,349 |
| Open | 91.40 |
| Previous Close | 92.44 |
| Day's Range | 91.38 - 92.28 |
| 52-Week Range | 62.38 - 94.16 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 93.92 (+2.43%) |
| Earnings Date | Aug 5, 2026 |
About SOLV
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for SOLV stock is "Buy." The 12-month stock price target is $93.92, which is an increase of 2.43% from the latest price.
News
Solventum management to meet with BTIG
Meeting to be held in Boston on September 10 hosted by BTIG.
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Solventum price target raised to $105 from $92 at Piper Sandler
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $105 from $92 and keeps an Overweight rating on the shares following quarterly results. Quarterly execution vs. Street continues…
Solventum price target raised to $101 from $94 at Wedbush
Wedbush analyst Michael Piccolo raised the firm’s price target on Solventum (SOLV) to $101 from $94 and keeps an Outperform rating on the shares. The firm notes the company reported…
Solventum price target raised to $100 from $90 at Stifel
Stifel raised the firm’s price target on Solventum (SOLV) to $100 from $90 and keeps a Buy rating on the shares.
Solventum price target raised to $101 from $95 at UBS
UBS analyst Patrick Wood raised the firm’s price target on Solventum (SOLV) to $101 from $95 and keeps a Buy rating on the shares. Solventum delivered a strong Q2 with…
Solventum price target raised to $84 from $81 at BMO Capital
BMO Capital raised the firm’s price target on Solventum (SOLV) to $84 from $81 and keeps a Market Perform rating on the shares. The HIS separation could unlock value by…
Solventum price target raised to $113 from $100 at Mizuho
Mizuho raised the firm’s price target on Solventum (SOLV) to $113 from $100 and keeps an Outperform rating on the shares.
Solventum price target raised to $102 from $93 at KeyBanc
KeyBanc raised the firm’s price target on Solventum (SOLV) to $102 from $93 on higher estimates and multiple, while keeping an Overweight rating on the shares. Despite noise around full-year…
Solventum price target raised to $95 from $91 at BTIG
BTIG analyst Ryan Zimmerman raised the firm’s price target on Solventum (SOLV) to $95 from $91 and keeps a Buy rating on the shares. Solventum reported better-than-expected Q2 results driven…
Solventum to hive off healthcare software business, raises profit forecast
Solventum , one of the largest providers of hospital consumables and sterilization devices, said on Wednesday it is planning to separate its health information systems business as part of its ongoin...
Solventum Earnings Call Transcript: Q2 2026
Q2 results exceeded expectations with strong organic growth, margin expansion, and robust performance across all segments. Guidance for 2026 was raised, reflecting confidence in continued growth, successful transformation progress, and the planned HIS separation to unlock value.
Solventum Earnings release: Q2 2026
Solventum released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Solventum Slides: Q2 2026
Solventum has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Solventum Quarterly report: Q2 2026
Solventum has published its Q2 2026 quarterly earnings report on August 5, 2026.
Solventum Shareholder letter: Q2 2026
Solventum has published a letter to shareholders covering Q2 2026, which was released on August 5, 2026.
Solventum raises FY26 adjusted EPS view to $7.10-$7.20 from $6.40-$6.60
FY26 consensus $6.55. Increased organic sales growth range to +2.5% to +3.0% (+3.5% to +4.0% excluding ~100 bps of SKU exit impact); from prior range of +2.0% to +3.0%. Increased…
Solventum intends to separate its Health Information Systems business
Solventum (SOLV) announced its intention to pursue a separation of its Health Information Systems business as part of the company’s ongoing portfolio optimization strategy. The company will evaluate a...
Solventum reports Q2 adjusted EPS $2.55, consensus $1.91
Reports Q2 revenue $2.2B, consensus $2.16B. The Solventum (SOLV) team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformatio...
Solventum Reports Second Quarter 2026 Financial Results
Reported sales increased 2.2%; organic sales increased 9.5% Announces intent to separate its Health Information Systems business segment Increases full-year 2026 guidance for organic sales growth, adj...
Solventum Announces Intent to Separate its Health Information Systems Business
Strengthens the focus of Solventum as a dedicated MedTech company and advances its three-phase transformation strategy Positions Health Information Systems, a leading, scaled, healthcare software busi...
Solventum assumed with Buy from Neutral at UBS
UBS upgraded Solventum (SOLV) to Buy from Neutral with a price target of $95, up from $78, after assuming coverage of the name. Solventum is “easy” to overlook, but “hard”…
Solventum assumed with Buy from Neutral at UBS
UBS upgraded Solventum (SOLV) to Buy from Neutral with a $95 price target after assuming coverage of the name.
Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
EAGAN, Minn., July 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.
Solventum price target raised to $91 from $89 at BTIG
BTIG raised the firm’s price target on Solventum (SOLV) to $91 from $89 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…